Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about NAMPT, SIRT1, C1QA/C1QB/C1QC, IL1B: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Target | Relation | Type | Str |
|---|---|---|---|
| No outgoing edges | |||
| Source | Relation | Type | Str |
|---|---|---|---|
| No incoming edges | |||
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Combined NAMPT-Alectinib Targeting of SASP-Complement Cascad | 0.549 | neuroinflammation | How does Alectinib, a kinase inhibitor, |
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| No experiments found | |||||||
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK [PMID:41824279] | ["Razak A", "Mahipal A", "Diamond JR", " | Target Oncol | 2026 | 0 |
| Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic st [PMID:25709099] | ["Sampath D", "Zabka TS", "Misner DL", " | Pharmacol Ther | 2015 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning NAMPT, SIRT1, C1QA/C1QB/C1QC, IL1B in their description or question text
No additional research found